Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women With Postmenopausal Osteoporosis

NCT05087030 is registered in ClinicalTrials.gov with Gedeon Richter Plc. as lead sponsor.

NCT NCT05087030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05087030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blind, Multicentre Phase III Study to Assess the Efficacy and Safety of RGB-14-P Compared to Prolia® in Women With Postmenopausal Osteoporosis
Lead sponsor
Gedeon Richter Plc.
Phase
Phase 3
Overall status
Completed
Start date
September 21, 2021
Completion date
November 15, 2023
Enrollment
473 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis